Page last updated: 2024-11-12
sq 14551
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
captopril disulfide : An organic disulfide in which the disulfide bond links two units of captopril. It is a secondary metabolite of captopril. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10002934 |
| SCHEMBL ID | 683117 |
| MeSH ID | M0109873 |
Synonyms (30)
| Synonym |
|---|
| captopril disulfide |
| sq 14,551 |
| 64806-05-9 |
| y21d2c2453 , |
| l-proline, 1,1'-(dithiobis(2-methyl-1-oxo-3,1-propanediyl))bis-(s-(r*,r*))- |
| unii-y21d2c2453 |
| 1,1'-[dithiobis[(2s)-2-methyl-1-oxo-3,1-propanediyl]]bis-l-proline captoprds |
| captopril disulfide [usp-rs] |
| captopril impurity a [ep impurity] |
| sq-14551 |
| l-proline, 1,1'-(dithiobis(2-methyl-1-oxo-3,1-propanediyl))bis-, (s-(r*,r*))- |
| 1,1'-(disulfanediylbis((2s)-2-methyl-1-oxopropane-3,1-diyl))bis((2s)-pyrrolidine-2-carboxylic) acid |
| l-proline, 1,1'-(dithiobis((2s)-2-methyl-1-oxo-3,1-propanediyl))bis- |
| captoprds |
| captopril impurity 2 |
| SCHEMBL683117 |
| l-proline, 1,1'-[dithiobis[(2s)-2-methyl-1-oxo-3,1-propanediyl]]bis- |
| AKOS028112522 |
| captopril imp. a (ep); captopril disulfide; 1,1'-[disulfanediylbis-[(2s)-2-methyl-1-oxopropane-3,1-diyl]]-bis[(2s)-pyrrolidine-2-carboxylic] acid; sq-14551; captopril impurity a |
| 1,1'-[disulfanediylbis-[(2s)-2-methyl-1-oxopropane-3,1-diyl]]-bis[(2s)-pyrrolidine-2-carboxylic] acid (captopril disulfide) |
| (2s)-1-[(2s)-3-[[(2s)-3-[(2s)-2-carboxypyrrolidin-1-yl]-2-methyl-3-oxopropyl]disulfanyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid |
| sq14,551 |
| sq-14,551 |
| 1,1'-{disulfanediylbis[(2s)-2-methyl-1-oxopropane-3,1-diyl]}bis-l-proline |
| (2's)-((2s,2's)-3,3'-disulfanediylbis(2-methylpropanoyl))di-l-proline |
| CS-0081128 |
| 1-[3-[[3-(2-carboxypyrrolidin-1-yl)-2-methyl-3-oxopropyl]disulfanyl]-2-methylpropanoyl]pyrrolidine-2-carboxylic acid |
| HY-123068 |
| DTXSID801024324 |
| 1,1'-[dithiobis[(2s)-2-methyl-1-oxo-3,1-propanediyl]]bis-l-proline |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The method has been used to determine the stability of captopril in oral liquid dosage forms prepared from either commercially available tablets or powder." | ( Stability of captopril in some aqueous systems. Bethea, C; Das Gupta, V; Pramar, Y, 1992) | 0.28 |
| "The absorption and metabolism of the disulfide dimer conjugate of captopril has been studied in the rat following both oral and intravenous dosing and compared with that of the active monomer, captopril." | ( Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat. Drummer, OH; Jarrott, B, 1984) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (16)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 10 (62.50) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.70
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.70) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||